Literature DB >> 24111806

Antagonistic and synergistic effects of bone morphogenetic protein 2/7 and all-trans retinoic acid on the osteogenic differentiation of rat bone marrow stromal cells.

Wenjuan Bi1, Zhiyuan Gu1,2, Yuanna Zheng2, Limin Wang3, Jing Guo4, Gang Wu5.   

Abstract

The osteogenesis of bone marrow stromal cells (BMSCs) is of paramount importance for the repair of large-size bone defects, which may be compromised by the dietary-accumulated all-trans retinoic acid (ATRA). We have shown that heterodimeric bone morphogenetic protein 2/7 (BMP2/7) could induce bone regeneration in a significantly higher dose-efficiency in comparison with homodimeric BMPs. In this study, we evaluated the effects of ATRA and BMP2/7 on the proliferation, differentiation, mineralization and osteogenic genes. ATRA and BMP2/7 exhibited both antagonistic and synergistic effects on the osteogenesis of BMSCs. ATRA significantly inhibited proliferation and expression of osteocalcin but enhanced the activity of alkaline phosphatase of BMSCs. On day 21, 50 ng/mL BMP2/7 could antagonize the inhibitive effects of ATRA and significantly enhance osteogenesis of BMSCs. These findings suggested a promising application potential of heterodimeric BMP2/7 in clinic to promote bone regeneration for the cases with dietary accumulated ATRA.
© 2013 The Authors Development, Growth & Differentiation © 2013 Japanese Society of Developmental Biologists.

Entities:  

Keywords:  all-trans retinoic acid; bone marrow stromal cells; bone morphogenetic protein; heterodimeric; osteogenic differentiation

Mesh:

Substances:

Year:  2013        PMID: 24111806     DOI: 10.1111/dgd.12090

Source DB:  PubMed          Journal:  Dev Growth Differ        ISSN: 0012-1592            Impact factor:   2.053


  7 in total

1.  Effects of heterodimeric bone morphogenetic protein-2/7 on osteogenesis of human adipose-derived stem cells.

Authors:  Xiao Zhang; Jing Guo; Gang Wu; Yongsheng Zhou
Journal:  Cell Prolif       Date:  2015-10-15       Impact factor: 6.831

Review 2.  Overview of Physical and Pharmacological Therapy in Enhancing Bone Regeneration Formation During Distraction Osteogenesis.

Authors:  Ze Liu; Qi Liu; Hongbin Guo; Jieyu Liang; Yi Zhang
Journal:  Front Cell Dev Biol       Date:  2022-04-28

3.  Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.

Authors:  Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2015-11-20       Impact factor: 22.113

4.  All-trans retinoic-acid inhibits heterodimeric bone morphogenetic protein 2/7-stimulated osteoclastogenesis, and resorption activity.

Authors:  Wenjuan Bi; Yi Liu; Jing Guo; Zhen Lin; Jinsong Liu; Miao Zhou; Daniel Wismeijer; Janak L Pathak; Gang Wu
Journal:  Cell Biosci       Date:  2018-08-23       Impact factor: 7.133

5.  All-trans retinoic acid can antagonize osteoblastogenesis induced by different BMPs irrespective of their dimerization types and dose-efficiencies.

Authors:  Yi Liu; Xiaoqing Ma; Jing Guo; Zhen Lin; Miao Zhou; Wenjuan Bi; Jinsong Liu; Jingxiao Wang; Haiping Lu; Gang Wu
Journal:  Drug Des Devel Ther       Date:  2018-10-10       Impact factor: 4.162

6.  All-trans retinoic acid and human salivary histatin-1 promote the spreading and osteogenic activities of pre-osteoblasts in vitro.

Authors:  Wei Sun; Andi Shi; Dandan Ma; Jan G M Bolscher; Kamran Nazmi; Enno C I Veerman; Floris J Bikker; Haiyan Lin; Gang Wu
Journal:  FEBS Open Bio       Date:  2020-02-11       Impact factor: 2.693

7.  The Antagonist of Retinoic Acid Receptor α, ER-50891 Antagonizes the Inhibitive Effect of All-Trans Retinoic Acid and Rescues Bone Morphogenetic Protein 2-Induced Osteoblastogenic Differentiation.

Authors:  Siqian Wang; Wenjuan Bi; Yi Liu; Jiayi Cheng; Wei Sun; Gang Wu; Xin Xu
Journal:  Drug Des Devel Ther       Date:  2020-01-22       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.